Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A real world study of osimertinib: ASTRIS 2nd DCO Korean subgroup analysis


24 Nov 2018


Poster display - Cocktail


Jong-Seok Lee


Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425


J. Lee1, B.C. Cho2, D. Kim3, K. Park4, J.H. Kang5, S.S. Yoo6, S.Y. Lee7, C.H. Kim8, S.H. Jang9, Y.C. Kim10, H. Yoon11, S. Kim12

Author affiliations

  • 1 Oncology/hematology, Seoul National University Bundang Hospital, 463-707 - Seongnam/KR
  • 2 Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR
  • 3 Department Of Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR
  • 4 Div. Of Heamatology/oncology, Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 5 Internal Medicine, The Catholic University of Korea, Seoul/KR
  • 6 Internal Medicine, Kyungpook National University, Daegu/KR
  • 7 Internal Medicine, Korea University Guro Hospital, Seoul/KR
  • 8 Internal Medicine, Koea Cancer Center Hospital, Ilsan/KR
  • 9 Internal Medicine, Hallym University Sacred Heart Hospital, Anyang/KR
  • 10 Internal Medicine, Chonnan National University Hwasun Hospital, Hwasun/KR
  • 11 Internal Medicine, The Catholic University of Korea, Yeouido St. Mary's hospital, Seoul/KR
  • 12 Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR



ASTRIS (NCT02474355) is a phase III, open-label, single-arm, multinational, real world study, investigating safety and efficacy of osimertinib in patients (pts) with T790M-positive advanced non-small cell lung cancer (NSCLC), who have previously received EGFR-TKI. As the largest real world study of osimertinib, ASTRIS has globally enrolled 3,014 pts; 466 were from Korea. We report the interim analysis (data cut-off (DCO): 20 Oct 2017) of Korean subset.


Eligible pts had advanced NSCLC with confirmed T790M mutation with no history of interstitial lung disease (ILD) or QTc prolongation. Pts with asymptomatic, stable CNS metastases were enrolled. Pts received osimertinib 80 mg once daily. The primary efficacy outcome was overall survival; other outcomes included investigator-assessed response rate (RR), progression-free survival (PFS), time to treatment discontinuation (TTD) and safety.


A total of 466 pts received at least one dose of osimertinib from 31 Korean sites. Baseline pts’ characteristics were median age 61.2 (27–85) years, 47.4% had prior chemotherapy and 46.8% had prior radiotherapy. At DCO, 236 pts (50.6%) were ongoing and median follow-up time was 11.6 (0–18) months. 49.4% had treatment discontinuation; median duration of exposure 11.2 (0–19) months, 35.2% had disease progression and 19.7% died. In pts evaluable for response, defined as at least one dose of osimertinib and one response assessment, the investigator-assessed RR was 71.0% (320/451; 95% CI 66.5 – 75.1). Median PFS and TTD were 12.4 months (10.6-13.6 months) and 15months (12.7-16.5). Due to limited follow-up period, OS was immature to analyze. Adverse events (AEs) leading to dose modification including treatment discontinuation was reported in 12.0%. Serious AEs were reported in 24.9% and AEs leading to death were reported in 2.8%. ILD/pneumonitis-like events were reported in 1.7%, and QTc prolongation (>470ms) in 1.5%.


With additional follow-up, ASTRIS Korean subgroup continues to demonstrate similar clinical activities (RR) and safety to that observed in the other osimertinib clinical trials.

Editorial acknowledgement

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings